Natalie Holles

President and Chief Operating Officer,
Audentes Therapeutics

Natalie has more than 20 years of experience in corporate development, strategic planning and operations leadership, with a particular focus on orphan diseases. She is currently president and chief operating officer of Audentes Therapeutics, Inc. Prior to joining Audentes, Natalie served as senior vice president, corporate development at Hyperion Therapeutics, Inc (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Natalie served as vice president, business development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. Natalie holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow, and an A.B. in human biology from Stanford University.